SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending following a clean double-beat earnings report, featuring record-breaking revenue and a significant $100 billion share buyback authorization. While some traders discuss potential volatility driven by supply chain constraints and the upcoming leadership transition, the community remains divided between those bullish on the company's capital return strategy and bears skeptical of the stock's valuation and growth trajectory.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending following a massive fiscal earnings beat and strong forward guidance that highlights sustained demand in the AI-driven data center storage sector. While the community is actively debating the sustainability of the stock's parabolic climb and the potential for a short-term sell-the-news correction, many investors remain focused on the company's pricing power and aggressive share buyback plans.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp (AKAN) is experiencing a massive short squeeze driven by extreme volatility, a low share float following multiple reverse splits, and high borrow fees that are forcing shorts to cover. The community is heavily focused on the stock's parabolic price action and speculative potential for further gains, while some traders caution that the volatility poses significant risks for those holding positions overnight.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is seeing intense trading activity driven by a massive earnings beat that featured significant growth in both revenue and active users, sparking debates among the community about whether the stock is a long-term monetization play or overdue for a price correction. Investors are closely monitoring its high volatility and the tension between fundamental performance and retail-driven market sentiment.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing heightened market scrutiny ahead of its upcoming earnings report as investors weigh the company's production milestones, including the R2 model ramp, against concerns over cash burn and executive compensation. While some community members remain optimistic about long-term potential and key strategic partnerships, others are actively debating the sustainability of current capital structures and the impact of potential dilution.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing significant downward pressure as investors scrutinize the company's growth outlook, monetization challenges, and persistent safety concerns, leading to a sharp sentiment reset that has many traders monitoring key technical support levels. The community is actively debating the platform's long-term viability, with vocal arguments splitting between those betting on an oversold bounce and those wary of structural deceleration and platform-wide moderation risks.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is currently experiencing significant market volatility and high trading volume following the announcement of a multi-million dollar milestone payment from their collaboration with Boehringer Ingelheim. Community sentiment remains polarized, with many traders closely monitoring the potential for a reverse stock split, while others are optimistic that the company's progress in autoimmune research and pending clinical trial milestones could drive a sustained rebound.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending following a significant quarterly earnings beat that surpassed analyst expectations for both revenue and EPS, signaling to investors that enterprise demand remains durable. The community is actively debating whether this performance marks a structural turnaround for the software sector or a temporary relief bounce, while discussions remain polarized over the long-term impact of AI on SaaS business models.

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

iSpecimen Inc

iSpecimen Inc. is attracting attention as traders track its low float and potential for volatility, with community sentiment divided between those anticipating a parabolic short squeeze and those skeptical due to ongoing downward price pressure and reverse split concerns. Speculation continues to swirl around possible strategic acquisitions or corporate news, keeping the ticker highly active despite the lack of official catalysts.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS is trending due to significant momentum and intense speculation regarding its micro-float status, with traders comparing its setup to other recent low-float runners. While some investors are banking on a squeeze and price appreciation, the community remains divided as others express caution over the company's history of dilution and weak financial fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Biotech Stocks To Follow Today - February 1st

Danaher, Vertex Pharmaceuticals, Moderna, Vaxcyte, argenex, VivoSim Labs, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks...

Biotech Stocks To Keep An Eye On - January 31st

Biotech Stocks To Follow Today - January 30th

Danaher, VivoSim Labs, Moderna, Vaxcyte, and Dianthus Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies...

<ul class="summary-bullets"><li>NAMKind human-based toxicology services is designed to help drug developers identify liver and gastrointestinal liabilities earlier in the development process.&nbsp;</li><li>The company also said that it is continuing to scale capacity to support expanding global demand.</li><li>The company also anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration announcement last year that sought to reduce animal testing requirements.</li></ul>Shares of VivoSim Labs, Inc. (VIVS) rose about 79% on Friday after the company announced expansion into Korea and China for its NAMKind toxicology services.VivoSims <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/29/3229075/0/en/VivoSim-Expands-Asia-Pacific-Access-to-NAMKind-Human-Based-Toxicology-Services-Through-New-Distributor-Agreement-in-Korea-and-China.html">said</a> on Friday that it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for NAMKind.<h2 class="st-heading-2">Expansion Details</h2>VivoSim Labs provides new approach methodologies for preclinical safety and NAMKind human-based toxicology services is designed to help drug developers identify liver and gastrointestinal liabilities earlier in the development process, helping avoid downstream failures.It also helps prioritize the right assets at the onset for pharmaceutical and biotechnology organizations.VivoSim said the new distributors will allow it to expand the company’s commercial presence across the Asia-Pacific.The company also said that it is continuing to scale capacity to support expanding global demand as drug developers seek earlier readouts, clearer translation to clinical outcomes, and meaningful reductions in late-stage attrition.The company also anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration announcement last year that sought to reduce animal testing requirements in favor of non-animal methods. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VIVS stock rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.“Not a bad session at all for momentum traders,” a Stocktwits user said. “Price moved cleanly higher. Buyers stayed in control.”<stembedurl>https://www.stocktwits.com/topstockalerts/message/643480801</stembedurl>Another user said they see a further rally up to $4.50.<stembedurl>https://www.stocktwits.com/MoeMoe66/message/643463733</stembedurl><a href="https://stocktwits.com/symbol/VIVS">VIVS stock</a> has lost about 27% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cort-shares-plummer-on-fda-drug-rejection-letter-reveal/cmySqTUR4SV">CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is VIVS Stock Up 79% Today?

VivoSims said on Friday that it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind human-based toxicology services.

Equity

VivoSims said on Friday that it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind human-based toxicology services.


VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.

VIVS
VivoSim Labs, Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest VIVS News

VIVSVivoSim Labs, Inc.